OncRef
Skip to newsletter content
|
mCRPCAugust 2026
0:00 / 2:11
Metastatic Castration Resistant Prostate Cancer — Monthly Compass
Aug 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in metastatic castration resistant prostate cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
metastatic castration resistant prostate cancer updates
Key Highlights
Key Highlights
  • Key Clinical Development Updates
    • FDA cleared Adicet Bio’s IND for ADI‑212, an allogeneic PSMA‑targeted Vδ1 γδ CAR T engineered with a novel binder, membrane‑tethered IL‑12 armoring, and CRISPR/Cas9 MED12 knockout, enabling a Phase 1/2 trial (NCT07793435) in mCRPC with U.S. enrollment starting Q4‑2026 and an initial site in Redwood City, California.
    • Telix reported TLX591‑Tx met ProstACT Global Part 1 safety/dosimetry objectives with FDA concurrence to open multi‑regional Part 2 sites (Australia, Canada, New Zealand, Singapore, South Korea, Türkiye, UK), while OPTIMAL‑PSMA (TLX597‑Tx) completed Phase 2 enrollment, collectively de‑risking late‑stage PSMA radioligand development.
  • Important Clinical Trial Publications
    • CheckPRO (CA209‑8TY) demonstrated no efficacy improvement from adding SBRT to nivolumab/ipilimumab in heavily pretreated mCRPC, with PSA/ORR/OS similar to IO doublet alone, inflammatory biomarkers (LDH, CRP, NLR) prognostic, and SBRT planning delays impairing delivery.
  • Emerging Themes & Macro-Trends
    • August updates underscore durable momentum of PSMA radioligand platforms and a decisive push into targeted protein degradation—evidenced by first‑patient dosing of MRT‑2359 plus apalutamide—while enthusiasm for IO+SBRT receded following a negative randomized readout.
    • Near‑term standard of care remains stable, but radioligand optimization and AR‑mutation–directed protein degradation could redefine post‑ARPI sequences as developers prioritize PSMA‑targeted platforms, AR‑mutation testing, and biomarker‑gated, registrational‑quality combinations.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-08-01 and 2026-08-31 about metastatic castration resistant prostate cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Adicet Bio announced FDA clearance of its IND for ADI-212, an allogeneic PSMA-targeted, gene-edited, armored gamma-delta CAR T for metastatic castration-resistant prostate cancer; the company plans to begin Phase 1 enrollment in Q4 2026. The update marks a regulatory milestone enabling first-in-human testing in mCRPC under the cleared IND. ¹ (adicetbio.gcs-web.com) (read more)
  • Urology Times reported that FDA IND clearance for Adicet’s ADI-212 “greenlights” a Phase 1/2 study in mCRPC (NCT07793435), with patient enrollment expected to start in Q4 2026. The article outlines key eligibility and dose-escalation details under the newly cleared IND. ² (urologytimes.com) (read more)
  • Yahoo Finance covered Adicet Bio’s announcement that the FDA cleared its IND for ADI-212 in advanced prostate cancer, summarizing the regulatory action and near-term trial start plans. The brief positions the clearance as a catalyst for initiating clinical evaluation in mCRPC. ³ (finance.yahoo.com) (read more)
  • BioWorld reported FDA clearance of Adicet’s IND for ADI-212 in mCRPC, noting the agency’s sign-off to proceed with clinical testing. The report reiterates the program’s focus and timing around study initiation in 2026. ⁴ (bioworld.com) (read more)
  • Earlier in the month, Adicet Bio’s Q2 2026 update stated it was on track to submit the ADI-212 regulatory filing for mCRPC in Q3 2026, with Phase 1 enrollment anticipated in Q4 2026 pending clearance. This corporate update framed the planned IND submission and subsequent startup activities now realized by month’s end. ⁵ (adicetbio.gcs-web.com) (read more)
  • Targeted Oncology’s August 2026 Brief included an item noting FDA IND clearance for ADI-212, a PSMA-targeted CAR T, in mCRPC, as Adicet readied 2026 enrollment. The brief further contextualized the program within ongoing IND-enabled development for prostate cancer. ⁶ (targetedonc.com) (read more)
Conference
Major Conference Updates
Conference Information
  • 26th Asia-Pacific Prostate Cancer Conference (APCC 2026); Melbourne Convention & Exhibition Centre, Melbourne, Australia; August 13–15, 2026. (read more)
  • August updates signal durable momentum for PSMA radioligand platforms and a decisive push into engineered cell and protein-degradation strategies for mCRPC, while interest in IO+SBRT combinations wanes after a negative randomized readout. (read more)
  • Theme 1: PSMA Radioligand Therapy Deepens and Diversifies
    • Significance: Radioligand therapy (RLT) remains an mCRPC backbone; multiple next‑gen lutetium agents advanced with regulatory alignment, reinforcing investment in PSMA‑targeted theranostics. (read more)
    • Mechanism insights / clinical impact: TLX591‑Tx (lutetium (177Lu) rosopatamab tetraxetan), a PSMA‑targeted rADC, met Part 1 ProstACT Global safety/dosimetry objectives; FDA concurrence enables Part 2, and OPTIMAL‑PSMA Phase 2 (TLX597‑Tx) completed enrollment—together suggesting platform maturity and room for dose/agent optimization. (read more)
    • Patient populations affected: PSMA‑positive mCRPC across multi‑regional Part 2 sites (Australia, Canada, New Zealand, Singapore, South Korea, Türkiye, UK), supporting broad geographic access planning. (read more)
  • Theme 2: Allogeneic PSMA CAR T Emerges
    • Significance: IND clearance for ADI‑212 introduces off‑the‑shelf γδ CAR T to mCRPC, potentially solving autologous manufacturing and time‑to‑treat barriers. (read more)
    • Mechanism insights / clinical impact: ADI‑212 (γδ Vδ1) integrates a novel PSMA binder, membrane‑tethered IL‑12 armoring, and CRISPR/Cas9 MED12 knockout—design features aimed at potency and TME remodeling; a phase 1/2 program is slated to start in Q4‑2026. (read more)
    • Patient populations affected: PSMA‑avid, progressive mCRPC with capped prior taxane/PSMA‑therapy exposure; initial US site in Redwood City, California. (read more)
  • Theme 3: Targeted Protein Degradation for AR‑Mutant Disease
    • Significance: Molecular glue degraders target translational dependency to address ARPI‑resistant biology; first patient dosing marks acceleration of this class in mCRPC. (read more)
    • Mechanism insights / clinical impact: MRT‑2359 degrades GSPT1, reducing AR/MYC; MODeFIRe‑1 evaluates MRT‑2359 + apalutamide in AR‑mutation–positive mCRPC, building on early combination data with enzalutamide that showed PSA responses in AR‑mutant subsets. (read more)
    • Patient populations affected: AR mutation–positive, previously treated mCRPC; design also contemplates future pairing with RLT regardless of AR status. (read more)
  • Theme 4: Recalibrating IO–Radiation Strategies
    • Significance: CheckPRO (CA209‑8TY) showed no efficacy gain from adding SBRT to nivolumab/ipilimumab, shifting focus toward biomarker‑enriched IO approaches and pragmatic trial logistics. (read more)
    • Mechanism insights / clinical impact: Similar PSA/ORR/OS to IO doublet alone; inflammatory biomarkers (LDH, CRP, NLR) were prognostic; SBRT planning delays hindered delivery—key operational learning for late‑line mCRPC. (read more)
    • Patient populations affected: Heavily pretreated mCRPC; future IO may center on MSI‑H/TMB‑high/DDR‑altered niches rather than unselected populations. (read more)
  • Significance
    • Expected clinical or translational readouts: ProstACT Global Part 2 progress (TLX591‑Tx), OPTIMAL‑PSMA analyses, MODeFIRe‑1 interim subset data by year‑end, and ADI‑212 first‑in‑human initiation in Q4‑2026. (read more)
    • Regulatory or policy implications: FDA alignment on TLX591‑Tx Part 2 de‑risks pivotal execution; IND clearance for ADI‑212 expands regulatory runway for cell therapy in solid tumors. (read more)
    • Potential shifts in standard of care: Near‑term SoC remains stable; radioligand optimization and AR‑mutant–directed degradation could redefine post‑ARPI sequences; IO+SBRT unlikely to advance without biomarkers. (read more)
    • Strategic implications: Prioritize PSMA‑targeted platforms (RLT, CAR T) and AR‑mutation testing; design registrational‑quality combinations (e.g., degrader+ARPI, RLT backbones) with biomarker gating to accelerate differentiation. (read more)
Publications Related to Approved Drugs
Phase 3
lutetium Lu 177 vipivotide tetraxetan
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. The PSMAddition trial demonstrated that adding [177Lu]Lu-PSMA-617 to standard androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) significantly prolonged radiographic progression-free survival in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. This combination therapy, despite a higher incidence of adverse events like dry mouth, presents a potential new standard of care for this patient population. () .
Phase 3
olaparib
Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel. In a sub-analysis of the Phase 3 PROpel trial, the combination of olaparib plus abiraterone showed a clinically meaningful improvement in radiographic progression-free survival and overall survival for first-line mCRPC patients, particularly those with BRCA2 mutations. These findings support the use of this combination as a first-line treatment option for biomarker-selected patients with mCRPC. () .
Phase 3
darolutamide
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial. Analysis of the ARASENS trial shows that adding darolutamide to ADT and docetaxel significantly delayed the time to metastatic castration-resistant prostate cancer (mCRPC) and pain progression compared to ADT and docetaxel alone. Importantly, this triplet therapy maintained health-related quality of life and demonstrated a favorable long-term safety profile, reinforcing its role as a standard-of-care option for patients with mHSPC. () .
Phase 3
apalutamide, enzalutamide
Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. This matching-adjusted indirect comparison of the ARCHES (enzalutamide) and TITAN (apalutamide) trials suggests broadly similar efficacy between the two agents in patients with mHSPC. While enzalutamide showed a potential improvement in radiographic progression-free survival, the overall survival and time to PSA progression were comparable, providing valuable data for treatment selection in the absence of a direct head-to-head trial. (, ) .
Phase 3
apalutamide
Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis. This post-hoc analysis of the TITAN trial proposes an integrated classification system combining CHAARTED and LATITUDE criteria, which improves prognostic stratification for overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC). While apalutamide showed a survival benefit across most risk groups, the findings are exploratory and highlight the need for prospective validation of this new risk stratification model. () .
New Publications Related to Drugs in Clinical Trial Development
Phase 2
A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer. In a Phase 2 trial for heavily pre-treated metastatic castration-resistant prostate cancer, the combination of the ATR inhibitor berzosertib with carboplatin resulted in a 0% overall response rate and higher toxicity compared to a 15% response rate for the docetaxel plus carboplatin arm, leading to the study's early termination for futility. Despite the negative outcome in a biomarker-unselected population, the study noted that ATM-deficiency or high pKAP1 levels were associated with clinical benefit, suggesting a potential targeted strategy for future investigations of this combination. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in metastatic castration resistant prostate cancer updated from 2026-08-01 to 2026-08-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting-11-1-3
Recruiting21117-8-47
Available-------
Approved for Marketing-------
Active, Not Recruiting62517-21
Completed-------
Total271413116-71
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
HRS-5041, Prednisone Acetate Tablets, Docetaxel injection, Abiraterone acetate tablets, Enzalutamide Soft Capsules NCT05942001 RECRUITING A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer 2026-09
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
No phase 2 trials completing within the next three months.
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
177Lu-PSMA-617, ARDT, 68Ga-PSMA-11 NCT04689828 ACTIVE_NOT_RECRUITING PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer 2026-09-10
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.